Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex)

Table 1

Table demonstrating visual acuity (measured using logMAR) and central macular thickness (CMT) measured using ocular coherence tomography in right eye of patient with macular telangiectasia type 1. Data is demonstrated at baseline, 2–6 weeks following each treatment, and after a recurrence of cystoid macular oedema (CMO).

Treatment	logMAR following treatment	CMT following treatment (𝜇m)	Time for recurrence of CMO after treatment	logMAR at recurrence of CMO	CMT at recurrence of CMO (𝜇m)
At baseline	0.3	353	N/A	N/A	N/A
Intravitreal bevacizumab	0.18	401	N/A	N/A	N/A
Intravitreal triamcinolone	0.48	282	8 weeks	0.48	397
Ozurdex	0.59	286	14 weeks	0.70	349
Ozurdex	0.64	279	18 weeks	0.74	332
Ozurdex	0.78	279	N/A	N/A	N/A